Hence, the use of PPSV23 has increased steadily in Taiwan, with the cumulative coverage rate among those aged ≥75 years almost doubling from 12% in 2007 to 20.8% in 2018, leading to a decreasing trend of IRs observed in the pre-PCV13 period and a significantly lower baseline IR observed in the post-PCV13 period [ 21 , 22 ].
← all excerpts
Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in Taiwan - a retrospective database study.
1
—
—